[go: up one dir, main page]

AR033168A1 - Solucion oral de aripiprazol - Google Patents

Solucion oral de aripiprazol

Info

Publication number
AR033168A1
AR033168A1 ARP020101366A ARP020101366A AR033168A1 AR 033168 A1 AR033168 A1 AR 033168A1 AR P020101366 A ARP020101366 A AR P020101366A AR P020101366 A ARP020101366 A AR P020101366A AR 033168 A1 AR033168 A1 AR 033168A1
Authority
AR
Argentina
Prior art keywords
solution
oral
aripiprazol
acid
aripiprazole
Prior art date
Application number
ARP020101366A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR033168A1 publication Critical patent/AR033168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se proporciona para una solucion farmacéutica adecuada para administracion oral que comprende aripiprazol, un sistema de solvente farmacéuticamente adecuado, uno o más agentes mejoradores/enmascarantes del sabor y uno o más agentes seleccionados del grupo que consiste de ácido láctico, ácido acético, ácido tartárico y ácido cítrico, en donde la solucion tiene un pH desde 2.5 hasta 4.5.
ARP020101366A 2001-04-25 2002-04-15 Solucion oral de aripiprazol AR033168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25

Publications (1)

Publication Number Publication Date
AR033168A1 true AR033168A1 (es) 2003-12-03

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101366A AR033168A1 (es) 2001-04-25 2002-04-15 Solucion oral de aripiprazol

Country Status (36)

Country Link
US (1) US6977257B2 (es)
EP (2) EP1381367B1 (es)
JP (1) JP4401077B2 (es)
KR (1) KR100909329B1 (es)
CN (1) CN1512884B (es)
AR (1) AR033168A1 (es)
AT (1) ATE537831T1 (es)
AU (1) AU2002254722B2 (es)
BG (1) BG66177B1 (es)
BR (1) BR0208986A (es)
CA (1) CA2445276C (es)
CY (1) CY1112606T1 (es)
CZ (1) CZ306181B6 (es)
DK (1) DK1381367T3 (es)
EE (1) EE05581B1 (es)
ES (1) ES2377855T3 (es)
GE (1) GEP20053602B (es)
HR (1) HRP20030870B1 (es)
HU (1) HU230456B1 (es)
IL (2) IL158202A0 (es)
IS (1) IS2863B (es)
MX (1) MXPA03009728A (es)
MY (1) MY129350A (es)
NO (1) NO324606B1 (es)
NZ (1) NZ528550A (es)
PE (1) PE20021086A1 (es)
PL (1) PL206882B1 (es)
PT (1) PT1381367E (es)
RS (1) RS52082B (es)
RU (1) RU2295960C2 (es)
SK (1) SK287948B6 (es)
TW (1) TWI337865B (es)
UA (1) UA76144C2 (es)
UY (1) UY27273A1 (es)
WO (1) WO2002085366A1 (es)
ZA (1) ZA200307797B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
BR0313602A (pt) * 2002-08-20 2005-06-21 Bristol Myers Squibb Co Método e formulação de complexo de aripiprazol
EP1680144B1 (en) * 2003-10-08 2011-10-05 Mallinckrodt LLC Methylphenidate solution and associated methods of administration and production
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
AU2005205933B2 (en) * 2004-01-21 2010-02-18 Elanco Animal Health Ireland Limited Mitratapide oral solution
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US20070154545A1 (en) * 2006-01-05 2007-07-05 Julia Hrakovsky Dry formulations of aripiprazole
ES2318693T5 (es) * 2006-01-05 2018-10-04 Teva Pharmaceutical Industries Ltd Procedimiento de granulación en húmedo para la preparación de composiciones farmacéuticas de aripiprazol
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
WO2007144874A1 (en) 2006-06-12 2007-12-21 Hadasit Medical Research Services And Development Ltd. Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
NO2170279T3 (es) * 2007-07-31 2018-05-26
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
AU2012231160B2 (en) 2011-03-18 2017-04-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2868319A4 (en) * 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
CN104736142B (zh) * 2012-09-26 2020-03-03 百时美-施贵宝控股爱尔兰无限公司 阿哌沙班液体制剂
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
WO2014060324A1 (en) 2012-10-16 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S Aripiprazole formulations
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3933027A1 (de) * 1989-09-29 1991-04-11 Schering Ag Kombinationspraeparat mit antithrombotischer wirkung
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (es) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
HUP0001739A3 (en) * 1997-03-31 2001-04-28 Johnson & Johnson Consumer Solvent system for enhanced penetration of pharmaceutical compounds for topical use and the use of the buffer solvent system
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
NZ528550A (en) 2005-03-24
RS52082B (sr) 2012-06-30
CY1112606T1 (el) 2016-02-10
EP2436384B2 (en) 2018-05-23
RU2003132426A (ru) 2005-04-20
CZ20032821A3 (cs) 2004-09-15
GEP20053602B (en) 2005-08-10
EP2436384A2 (en) 2012-04-04
HRP20030870A2 (en) 2004-06-30
IS2863B (is) 2013-12-15
HU230456B1 (hu) 2016-07-28
TWI337865B (en) 2011-03-01
HK1168792A1 (en) 2013-01-11
HK1058316A1 (en) 2004-05-14
EP2436384A3 (en) 2012-09-19
YU84703A (sh) 2006-08-17
AU2002254722B2 (en) 2006-11-09
MXPA03009728A (es) 2004-01-29
EP1381367A1 (en) 2004-01-21
ES2377855T3 (es) 2012-04-02
PE20021086A1 (es) 2002-12-14
EE05581B1 (et) 2012-10-15
KR100909329B1 (ko) 2009-07-24
KR20030096332A (ko) 2003-12-24
SK12642003A3 (sk) 2004-07-07
CZ306181B6 (cs) 2016-09-14
BR0208986A (pt) 2004-04-20
IL158202A0 (en) 2004-05-12
ZA200307797B (en) 2004-10-06
HUP0303946A3 (en) 2005-06-28
SK287948B6 (sk) 2012-06-04
CN1512884A (zh) 2004-07-14
NO324606B1 (no) 2007-11-26
NO20034705L (no) 2003-11-28
UA76144C2 (uk) 2006-07-17
US20020193438A1 (en) 2002-12-19
BG108216A (bg) 2004-12-30
US6977257B2 (en) 2005-12-20
WO2002085366A1 (en) 2002-10-31
EP1381367B1 (en) 2011-12-21
EP1381367A4 (en) 2009-07-01
EP2436384B1 (en) 2015-06-10
IS6994A (is) 2003-10-14
CA2445276A1 (en) 2002-10-31
NO20034705D0 (no) 2003-10-21
PT1381367E (pt) 2012-03-01
EE200300523A (et) 2004-02-16
JP4401077B2 (ja) 2010-01-20
JP2004532225A (ja) 2004-10-21
HUP0303946A2 (hu) 2004-04-28
ATE537831T1 (de) 2012-01-15
RU2295960C2 (ru) 2007-03-27
MY129350A (en) 2007-03-30
PL206882B1 (pl) 2010-10-29
PL364666A1 (en) 2004-12-13
DK1381367T3 (da) 2012-04-10
UY27273A1 (es) 2002-11-29
CA2445276C (en) 2009-10-13
BG66177B1 (bg) 2011-11-30
CN1512884B (zh) 2010-05-26
HRP20030870B1 (en) 2011-10-31
IL158202A (en) 2008-04-13

Similar Documents

Publication Publication Date Title
AR033168A1 (es) Solucion oral de aripiprazol
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
MA26995A1 (fr) Derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
GEP20063895B (en) Platinum derivative pharmaceutical formulations
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
HUP0203716A2 (hu) Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények
DE60202603D1 (de) 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, verfahren zur isolation aus pterocarpus marsupium und pharmazeutische zusammensetzung zur behandlung von diabetes
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ATE454151T1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion
EE200300065A (et) Meetod peptiidsoolade valmistamiseks, nende peptiidsoolade kasutamine ning neid peptiidsooli sisaldavad farmatseutilised preparaadid
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
ES2064619T3 (es) Derivados tetrahidropiranilicos, procedimiento para su preparacion y composiciones farmaceuticas o veterinarias que los contienen.
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
ATE484516T1 (de) 3.beta.,28-diacetoxy-18-oxo-19,20,21,29,30- pentanorlupan-22-säure solvate, verfahren zu ihrer herstellung und pharmazeutische präparate daraus
RU99127690A (ru) Способ лечения опийной наркомании
ATE302183T1 (de) Indenoindolin derivate, verfahren zur herstellung dieser derivate und diese enthaltende pharmazeutische präparate
SE9902674D0 (sv) New composition
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten